InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,657.42
(
0.41%
)
US TECH 100
19,061.20
(
0.64%
)
Dow Jones
41,726.35
(
0.29%
)
Brent Oil
72.90
(
-0.58%
)
Bitcoin
60,947.61
(
1.07%
)
Post# of 253146
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

drbio45

Send PM Follow Ignore
Followers 36
Posts 3185
Boards Moderated 0
Alias Born 10/18/2003

drbio45

Re: RockRat post# 35619

Monday, 10/16/2006 3:26:44 PM

Monday, October 16, 2006 3:26:44 PM

Post# of 253146
ENCY – The warfarin interaction remains an issue, IMO. From your SI post:

>>
The AUC0-inf of S-warfarin (25 mg) increased with sitaxentan administration with 95%, for 100 mg once daily doses of sitaxentan (study FNL02). Also the terminal half-life of warfarin increased after sitaxentan co-administration.
<<


he is correct but it is manageable. they reduce the dose of warfarin to manage the interaction. The fda should be more concerned with the higher lft's of tracleer and the fact that people can stay on the drug for a longer period of time
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up